LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added ...
PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate ...
The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
Primary staging of patients with high-risk PCa prior to initial curative therapy To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific ...
ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...
ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, ...
Curium Pharma, the CapVest Partners-backed nuclear medicine imaging company, is poised to field first round bids early next week, people with knowledge of the matter told PE Hub. A process formally ...
Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre ...
BUFFALO, N.Y. and TALLAHASSEE, Fla. — New research shows that curium — one of the heaviest known elements — can be manipulated to a larger degree than previously thought. An international team ...
Curium will shortly open a new facility to manufacture cutting-edge diagnosis technology for diseases like cancer at the Churchill Hospital site, part of Oxford University Hospitals NHS Foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results